Nikki Wood

Pediatric Hematology/Oncology Physician at CMH in KCMO.

[Nikki Wood @WoodNikkiM]

Where Privacy Meets Partnership in Adolescent Oncology Portal Use | JCO Clinical Cancer Informatics https://t.co/xvmfP8csB8

[S. Trent Rosenbloom @trentrosenbloom]

Join us at 3pm for a lively debate about patient immediate access to their cancer test results. #CIC24

[out of context the office @adidaspartners]

@BoredApeYC 🏁Reminder: Gary the Dog invites all holders to register now for Game 3:

"Something is brewing in the swamp 👀"

🔗https://t.co/umVGc5LLGy

🎮 Game continues!

[Nikki Wood @WoodNikkiM]

@adidaspartners @BoredApeYC BAYC BROSSS

[out of context the office @adidaspartners]

@BoredApeYC 🏁Reminder: Gary the Dog invites all holders to register now for Game 3:

"Something is brewing in the swamp 👀"

🔗https://t.co/umVGc5LLGy

🎮 Game continues!

[Annals of Oncology @Annals_Oncology]

When is crossover desirable in cancer drug trials and when is it problematic? Read the editorial by @VinayPrasadMD https://t.co/qBzwxSseeK

[Annals of Oncology @Annals_Oncology]

In the last few years, growth of research into liquid biopsies and diagnostics has been exponential - read the latest blog post from Annals of Oncology on the subject https://t.co/fGu4sFYU2U #liquidbiopsy

[Nikki Wood @WoodNikkiM]

I am always interested in ways to make consenting a bit less cumbersome on families. @UMKCBioMed #umkcclintrial https://t.co/zoY2UQJsRB

[Nikki Wood @WoodNikkiM]

promising gene therapy for beta thal. @UMKCBioMed #UMKCClinTrial https://t.co/EFrjaiIOla

[NEJM @NEJM]

New research into gene therapy in patients with transfusion-dependent β-thalassemia explained in Quick Take video: https://t.co/a2903TdhWw

[Nikki Wood @WoodNikkiM]

Targeted therapy is hopefully in the future for HLH. #umkcclintrial @UMKCBioMed https://t.co/oX0Bpk9zzn

[ASH @ASH_hematology]

Emergence of targeted therapy for hemophagocytic lymphohistiocytosis https://t.co/3NtJJkaif5 via The Hematologist

[Nikki Wood @WoodNikkiM]

Hot off the press. @UMKCBioMed #umkcclintrial https://t.co/wraiZvaJaU

[Nikki Wood @WoodNikkiM]

@UMKCBioMed #UMKCClinTrial https://t.co/4dbMel3o6L

[National Cancer Institute @theNCI]

Most cancer drugs launched between 2009 and 2014 cost more than $100,000 per patient for a year's treatment, as Dr. Barbara Rimer explains: https://t.co/fB6P8MHvIW @PresCancerPanel

[Nikki Wood @WoodNikkiM]

@UMKCBioMed #UMKCClinTrial https://t.co/YDcYAlyhms

[JAMA Oncology @JAMAOnc]

Study of 100 press releases of #clinicaltrials sponsored by pharmaceutical companies shows median interval of 300 days between initial announcement and availability of peer-reviewed publication of data. Read more https://t.co/Nqx2N7qRyt

[Nikki Wood @WoodNikkiM]

@UMKCBioMed #umkcclintrial https://t.co/7EO4GGuRcF

[ASH Clinical News @ASHClinicalNews]

In a @BloodAdvances study, researchers ask if there's an advantage with newer direct oral anticoagulants over warfarin https://t.co/my7nqVgk7r

[Nikki Wood @WoodNikkiM]

@UMMCnews #umkcclintrial https://t.co/rXdJYk7fqt

[National Cancer Institute @theNCI]

New #immunotherapy drug simultaneously targets two proteins that block the body's immune response against tumors: https://t.co/nuPkodR4S9

[Nikki Wood @WoodNikkiM]

More in the AI world of things. @UMKCBioMed #umkcclintrial https://t.co/OFMNbcskyi

[Eric Topol @EricTopol]

The 1st @US_FDA approved deep learning #AI device for 1°care today: diagnosis of diabetic retinopathy w/o ophthalmologists. https://t.co/5ooQJhXM7l
But no published data. Website claims 87% sensitivity, 90% specificity from 900 patient trial.
+ @SGottliebFDA's upbeat #AI tweets.

[Nikki Wood @WoodNikkiM]

Some great points about the premature hype with experimental drugs. @UMKCBioMed #umkcclintrial https://t.co/R3BhpvAlJf

[HealthNewsReview @HealthNewsRevu]

A cancer doctor speaks out: How premature hype about experimental drugs fails patients https://t.co/61sKabPxs9 w/ @VinayPrasadMD

[Nikki Wood @WoodNikkiM]

No luck with added hepatic arterial infusion chemo in HCC @UMKCBioMed #umkcclintrial https://t.co/Z9iHxZpnOL

[The Lancet Gastroenterology & Hepatology @LancetGastroHep]

New: Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced #hepatocellularcarcinoma - the SILIUS phase 3 trial - https://t.co/vky7H1lCUn #livercancer

[Nikki Wood @WoodNikkiM]

@UMKCBioMed #umkcclintrial https://t.co/hLP5PGneJB

[Annals of Oncology @Annals_Oncology]

Artificial intelligence in oncology; read the latest blog post from Annals of Oncology on how #AI is being used for rapid diagnosis and optimum treatment proposals for cancer patients https://t.co/xwqRVcxea5 #oncology

[Nikki Wood @WoodNikkiM]

@UMKCBioMed #umkcclintrial https://t.co/JOLgcDWhg4

[ASH Clinical News @ASHClinicalNews]

Contract research organizations are an easy target for researchers’ frustrations, but are CROs victims of the same bureaucracy plaguing investigators and research sites? https://t.co/xreWIX4T98